Retrospective cohort analysis comparing the incidence of deep vein thromboses between peripherally-inserted and long-term skin tunneled venous catheters in hemato-oncology patients by Priya Sriskandarajah et al.
Sriskandarajah et al. Thrombosis Journal  (2015) 13:21 
DOI 10.1186/s12959-015-0052-2ORIGINAL CLINICAL INVESTIGATION Open AccessRetrospective cohort analysis comparing the
incidence of deep vein thromboses between
peripherally-inserted and long-term skin tunneled
venous catheters in hemato-oncology patients
Priya Sriskandarajah1*, Katharine Webb1, David Chisholm2, Ravi Raobaikady2, Kim Davis1, Natalie Pepper1,
Mark E Ethell1, Mike N Potter1 and Bronwen E Shaw1Abstract
Background: The introduction of central venous catheters has advanced medical care, particularly in hemato-oncology.
However these can be associated with an increased thrombotic risk. Previous studies have compared the rate of
thrombotic events between peripherally- inserted (PICCs) and long term skin tunneled catheters (LTSTCs) noting fewer
complications associated with the latter, though this has rarely translated into clinical practice. The objectives of our
study was to compare the cumulative incidence of thrombotic events between peripherally-inserted and long term
skin tunneled venous catheters.
Patients/methods: We performed a retrospective, single center cohort analysis of patients with hematological
malignancies who had either a PICC or LTSTC line inserted between January 2010 through January 2013. Cumulative
incidences of thrombotic events were compared between the two groups, and post-thrombotic complications were
also examined.
Results: 346 patients had a PICC inserted with cumulative incidence of symptomatic thrombosis of 5.8%, while 237
patients had a LTSTC inserted with a cumulative incidence of 1.7% (p = 0.003). Post-thrombotic complication rates,
particularly infection, were higher in the PICC group compared to the LTSTC group (p = 0.597).
Conclusions: Our study showed that the incidence of thrombotic events in hemato-oncology patients was significantly
lower in those who had a LTSTC compared to PICC line. As the use of central venous lines increases in hemato-oncology
patient care, a randomized trial comparing PICCs and LTSTCs is necessary to address which venous access is most
appropriate in this cohort of patients, with minimal risk of morbidity and mortality.
Keywords: Catheter-related deep vein thrombosis, Cohort study, Doppler ultrasonography, Long term skin tunneled
catheterisation, Venous thromboembolismBackground
The introduction of long term central venous catheters
has been one of the most significant advances in medical
care leading to its widespread use in a broad range of
diseases, including infections and malignancies. Unfortu-
nately, the use of these catheters can be associated with* Correspondence: psriskandarajah@googlemail.com
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article, unless otherwise stated.complications, most notably the development of a
catheter-related deep vein thrombosis (DVT).
The reported incidence of catheter-related thrombosis
(CRT) has been highly variable, ranging from 12-60% in
various studies [1,2]. However, it has been commonly
noted that patients with malignancy are at an increased
risk of developing this complication [3,4]. Furthermore,
the impact of a thrombotic event can be clinically sig-
nificant, particularly in hemato-oncology patients, as
they require long-term access for the administration of
blood products, chemotherapy and stem cell rescue.Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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with hematological malignancies has been limited [5–7].
In 2010, Tran et al. were one of the first groups to
examine the incidence of CRTs in hemato-oncology
patients following insertion of either a long term skin
tunneled (LTSTC) or peripheral (PICC) central venous
catheter [8]. They found that the incidence of throm-
botic events was higher in those with a peripheral com-
pared to central line, with the majority of patients
managed by initiating anticoagulation. Several studies
have supported these findings with reported rates of
asymptomatic and symptomatic PICC-related throm-
boses of up to 50% and 22% respectively [9–12].
Despite these data however this has rarely translated into
clinical practice with the majority of UK hospitals electing
to use PICCs as the procedure is considered less invasive.
This is due to the reported increased incidence (approxi-
mately 3%) of serious mechanical complications in patients
undergoing central venous catheter (CVC) placement, in-
cluding arterial puncture (incidence range 3.1-15%) and
pneumothorax (incidence range 0.1-3.1%) [13,14].
Nevertheless the risk of catheter-related thrombosis is
not insignificant and can be associated with significant pa-
tient morbidity and potential mortality [15]. Based on the
current literature, it is likely that the incidence of throm-
boses will be higher in PICCs compared to LTSTCs, but
more data is required [16–18]. Accordingly we performed
a retrospective cohort study comparing the cumulative
incidence of thrombotic events following insertion of
either a PICC or LTSTC line in hemato-oncology patients.
We also analyzed secondary outcomes including post-
thrombotic infection and pulmonary emboli.
Patients/methods
Study design
This cohort study and waiver of informed consent was ap-
proved by the Royal Marsden Audit Review Committee.
Data were obtained by retrospective review of paper and
electronic medical records for all hemato-oncology pa-
tients admitted to Royal Marsden Hospital who had either
a PICC or LTSTC line insertion between 1st January 2010
to 1st January 2013. Only the first line placed during
hospitalization was included in this study to avoid error
that may be due to a previous catheterization at another
site. Symptomatic thrombosis was determined by review-
ing the duplex ultrasound reports for every patient who
had a PICC or LTSTC inserted. A catheter-related throm-
bosis was defined as an acute proximal large vein throm-
bosis in association with the catheter confirmed by duplex
ultrasonagraphy.
Primary outcome
The primary outcome was the occurrence of a symp-
tomatic catheter-related thrombosis.Secondary outcomes
The secondary outcomes were the occurrence of post-
thrombotic complications, namely Infection, Hemorrhage,
Pulmonary Embolism and Line Removal. Similar to pre-
vious studies, line-associated infection was defined as
identification of the same bacteria cultured from the line
as well as from one or more blood cultures not drawn
from the line and with no other identifiable source for the
bloodstream infection [14].
Data collected
The data collected in addition to the primary and secondary
outcomes included age, gender, underlying hematological
malignancy, disease stage and duration of dwell time of
the line. Previous studies had identified other risk factors
associated with thrombosis including history of venous
thromboembolic events, type of chemotherapy received
and concomitant medication (including anti-platelet the-
rapy and low-molecular weight heparin) [3,19]. Subse-
quently we collected these factors for comparison also.
Statistical analysis
All data was entered into a spreadsheet audit tool. Sum-
mary statistics for quantitative data are described as a
median with range, while nominal data are expressed as
a percentage. Log-rank test was used to compare Kaplan
Meier of the 2 groups while Fishers’ exact test was used
to compare the complication rates in the groups. Due to
the low number of outcomes, multivariate analysis was




During the study period 583 hemato-oncology patients
had a line inserted at Royal Marsden Hospital, of which
346 had a PICC and 237 had a LTSTC. The baseline
characteristics for these two groups have been summa-
rized in Table 1. These were generally similar between
the two groups, with the majority of our patients being
diagnosed with AML and having relapsed/refractory
disease. Notably the dwell time of line was significantly
longer in the LTSTC group (median 109.4 days) com-
pared to the PICC group (median 64.9 days).
Primary outcome
In those who had a PICC line inserted, 20 (5.6%) pa-
tients developed a catheter-related thrombosis, while in
comparison only 4 (1.7%) patients developed this follo-
wing LTSTC insertion, which was a statistically signifi-
cant difference (p = 0.003) (Figure 1).
The median follow-up time for PICC patients was 53 days
(95% CI: 44-62 days) with an initial 30-day incidence of
DVT of 5% (of total number of PICC patients, n = 346),
Table 1 Baseline characteristics for all hemato-oncology
patients undergoing line insertion
Patient characteristics PICC (n = 346) LTSTC (n = 237)
Median age (range) 49.7 (15-77) 50.8 (17-72)
Gender:
Females (%) 49 49
Males (%) 51 51
Hematological malignancy:
AML (%) 36 25
ALL (%) 14 10
HL (%) 5 7
NHL (%) 24 15
MM (%) 15 27
Chronic leukemia (%) 4 9
Misc (%) 2 7
Disease stage:
Newly diagnosed (%) 27 10
Relapsed/Refractory (%) 52 53
Remission (%) 21 37
Median duration of dwell time
of line in days (range)
64.9 (1-519) 109.4 (1-783)
NB: AML = Acute Myeloid Leukemia; ALL = Acute Lymphoblastic Leukemia;
HL = Hodgkin Lymphoma; NHL = Non-Hodgkin Lymphoma; MM =Multiple
Myeloma; Misc. = Miscellaneous consisting of Myelofibrosis, Myelodysplastic
Syndrome and Aplastic Anemia; Chronic Leukemia consisting of Chronic
Myelomonocytic Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic
Leukemia and T-Prolymphocytic Leukemia; PICC = Peripherally-Inserted Central
Venous Catheter; LTSTC = Long-term skin-tunneled venous catheter.
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number of patients presenting with catheter-related throm-
bosis increased the longer their PICC line was kept in.
Similar results were seen in LTSTC patients though
the incidence rates were lower, where over a median
follow-up period of 97 days (95% CI: 78-116 days) the
30-day incidence was only 1% (of total number of
LTSTC patients, n = 237). This subsequently increased
to 6% during the review period of 27 months, thus
highlighting that the cumulative risk of thrombosis in
this group did increase with time but at a slower rate.
Risk factors associated with line-related thrombosis
In Table 2 we compared the prevalence of risk factors in
patients who developed either a PICC or LTSTC related
thrombosis. These factors were based on previous stu-
dies which examined thrombotic events in patients with
malignancy [3,19]. There was no difference in the num-
ber of patients who were receiving Immunomodulatory
Drugs (IMiDs) or anti-coagulant prophylaxis prior to
developing a thrombosis. However there was a notable
difference between the two groups with respect to prior
history of venous thromboembolism (VTE), with this
risk factor being more prevalent in the PICC comparedto LTSTC group. Overall, however, these risk factors
were found not to be statistically significant (p = 0.121).
Other risk factors to consider include the type of under-
lying hematological malignancy. As shown in Table 1
there were a higher number of AML patients in the PICC
group in comparison to the LTSTC group, while this was
vice versa for patients with Multiple Myeloma, and this
may potentially influence thrombosis risk. However, given
the small number of outcomes, further statistical analysis
to confirm whether this factor had an impact on throm-
bosis risk could not be performed.
Another risk factor is the stage of disease. Previously,
it has been noted that patients with newly diagnosed dis-
ease are often at greatest risk of thrombosis, particularly
within the first 3 months [3]. We examined the rates
of catheter-related thrombosis between the following
groups: Newly Diagnosed, Relapse and Remission. The
rate of thrombosis between these groups were 5.3% vs
6.1% vs 6.5% respectively, which was not statistically sig-
nificant (p = 0.958), suggesting that this did not influence
thrombosis risk.Secondary outcomes
None of the LTSTC or PICC patients who had a catheter-
related thrombosis developed a subsequent pulmonary
embolism (PE). There were 9 (45%) line-related infections
in the PICC group compared to 1 (20%) in the LTSTC
group. Furthermore, 16 (80%) of the PICC compared to 2
(50%) of the LTSTC group had their line removed follo-
wing a thrombotic event.
All patients who developed a catheter-related throm-
bosis were managed with 3-month therapeutic dose
anticoagulation. At diagnosis, the median platelet count
for these patients was 124.6×109/L (range 15-320×109/L)
with all having a normal clotting range. There were no
documented hemorrhagic complications associated with
treatment, and none of our patients required thromboly-
sis or inferior vena cava (IVC) filter insertion.
Overall there was no statistically significant difference
in the rates of post-thrombotic complications between
the PICC and LTSTC groups (p = 0.597).Discussion
Over the years there has been an increasing use of
PICCs due to the procedure being less invasive and the
relatively low rate of line-related complications. Within
our hospital trust, the current policy is to use PICCs first
line, particularly for newly diagnosed patients who re-
quire urgent treatment, while LTSTCs are reserved for
those undergoing stem cell rescue. However the risk of
catheter-related thrombosis is often not considered. This
is an important complication, especially in hemato-
oncology patients, as it can potentially result in delayed
Figure 1 Kaplan Meier Plots comparing the cumulative incidence of DVT events between patients who had either a PICC or LTSTC (e.g. Hickman) line
inserted. A total 583 patients were identified within the reviewing period, of which 346 had PICC and 237 had LTSTC. Log rank test p = 0.003. NB: PICC =
peripherally-inserted central venous catheter; LTSTC = long term skin tunneled catheter (i.e. Hickman line).
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hazards of therapeutic anticoagulation [20].
When examining the current literature, there is mini-
mal data available regarding the incidence of catheter-
related thrombosis in hemato-oncology patients. There
are studies which have been performed in critical careTable 2 Prevalence of risk factors in patients who
developed a line-related thrombosis
Risk factor Number of
patients in PICC





Known background of inherited
prothrombotic conditions (%)
0 (0) 0 (0)
History of VTE or PE (%) 2 (10) 0 (0)
Chemotherapy administered (%):
Immunomodulatory drug 2 (10) 2 (10)
Hormonal therapy 0 (0) 0 (0)
Anti-platelet therapy (%) 0 (0) 0 (0)
Anti-coagulant prophylaxis
(LMWH) (%)
2 (10) 2 (10)
NB: PICC = Peripherally-Inserted Central Venous Catheter; LTSTC = Long Term
Skin Tunneled Catheter; VTE = Venous Thromboembolism; PE = Pulmonary
Embolism; LMWH = Low-Molecular Weight Heparin.patients, with one case-control study reporting a throm-
botic incidence of 2.8% in PICCs compared to 0% in
LTSTCs [21]. Furthermore, a prospective randomized
controlled trial in post-critical care patients who had
routine surveillance for catheter-related thromboses also
observed a higher incidence of thrombotic events in
PICCs compared to short term CVCs (27.2% versus
9.6% respectively) [22].
Ours is the largest most recent study which has fo-
cused on comparing the incidence of catheter-related
thromboses in hemato-oncology patients. The data we
have produced is similar to previous studies, suggesting
that PICCs confer an increased risk of catheter-related
thrombosis compared to LTSTCs. Furthermore the ma-
jority of our patients in both groups presented within
the first 100 days of insertion, with the cumulative inci-
dence of thrombosis increasing over time. This would
suggest an association between dwell time of line and
risk of thromboembolic event, although interestingly the
dwell time of line was significantly longer in the LTSTC
group compared to the PICC group.
When considering the association between dwell time
and risk of thrombotic event there has been mixed data,
with some studies showing an association between
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while others have not. Overall the data produced so far
does seem to favor a lack of an association between
dwell time and risk of thrombosis [12,22,23]. However,
within our own study, we were unable to exclude the
possibility that longer dwell time contributed towards
increased thrombotic risk as we were unable to perform
an adjusted analysis.
There has been considerable interest in identifying other
potential risk factors for thromboembolism, particularly in
cancer patients, in order to prevent thrombotic events.
These have been sub-divided into three categories: Patient-
related, Disease-related and Treatment-related [3,19]. Given
that we were examining hemato-oncology patients, we
particularly focused on patient- and treatment-related risk
factors, which included known inherited prothrombotic
states, prior history of venous thromboembolic event and
use of immunomodulatory drugs. Though it was unclear
whether these risk factors would have the same impact in
patients with central venous catheters, we assumed that
these factors would contribute towards thromboembolic
risk and therefore documented the incidence of each of
these risk factors in both the PICC and LTSTC group.
The use of IMiDs and anti-coagulant prophylaxis oc-
curred with equal frequency in both groups, with none of
our patients having a known inherited prothrombotic con-
dition. However history of venous thromboembolism oc-
curred more frequently in the PICC group compared to
the LTSTC group, suggesting this is a contributing factor,
despite it not being statistically significant.
Another point to consider in hemato-oncology patients
is not only the risk of developing a catheter-related throm-
bosis, but the potential complications which can follow
this. Our secondary outcomes examined the incidence of
line-related infection, line removal, major hemorrhage and
pulmonary embolism in hemato-oncology patients follo-
wing development of a catheter-related thrombosis.
The risk of line-related infection has been previously
shown to be significantly increased in those with a
thrombosis, with colonization and sepsis rates reportedly
doubling [24–26]. This would be further enhanced in
hemato-oncology patients as they frequently have severe
and long-lasting neutropenia, placing them at greater
risk of infective complications generally. Our data re-
flected this with 9 patients in the PICC group compared
to only 1 in the LTSTC group developing line-related in-
fection following a thrombotic event, with all of these
patients subsequently having their line removed.
Given that our unit performs a large number of stem
cell rescues (over 200 per year), we also examined
whether development of a thrombosis had an impact on
the patient’s treatment plan. Of those who developed a
catheter-related thrombosis, 4 patients from the PICC
group had their treatment delayed, which included 3stem cell rescues. The median duration of treatment
delay was 13.8 days (range 4-20 days), which ultimately
will have resulted in prolonged hospitalization, although
this was not formally analyzed within our study. Hence
this highlighted not only the short-term impact of a
catheter-related thrombosis, but the potential long-term
consequences also with delays to treatment. Therefore,
this is another factor which needs to be taken into con-
sideration when determining the type of venous access
for a hemato-oncology patient.
The high rate of thrombosis in cancer patients with
central venous access has led to several studies exami-
ning the potential use of systemic anticoagulant therapy
[2]. Warfarin had previously been shown to successfully
reduce the risk of catheter-related thrombosis in patients
with solid tumors [27]. However, this can be a risky
strategy in hematological patients, due to the intermit-
tent and prolonged periods of chemotherapy-induced
thrombocytopenia.
Abdelkefi et al. were able to overcome this in a well-
controlled hospital setting where hemato-oncology pa-
tients were randomized to receive either intravenous
unfractionated heparin or normal saline infusions daily,
with a significantly lower incidence of catheter-related
thrombosis reported in the former compared to the lat-
ter group (1.5% versus 12.6% respectively) [28]. Further-
more, there were no reported significant bleeding
events, suggesting that low-dose unfractionated heparin
could be safely administered in this group of patients.
Our own data supports the safe use of therapeutic anti-
coagulation as we reported no major bleeding events,
despite our patients being thrombocytopenic.
More recent studies, however, have shown no benefit
from thromboprophylaxis in preventing catheter throm-
bosis [29–31]. All of these were double blind trials,
hence providing higher quality evidence compared to
the earlier published randomized trials which were not
blinded. Therefore, given these conflicting results, the
current guidelines released by the American College of
Chest Physicians (ACCP) do not recommend the routine
use of anticoagulation in cancer patients with central
venous lines until additional randomized controlled
trials can confirm that the benefits of anticoagulation
outweigh the risks [32].
Given that our study was retrospective, the greatest
limitation was the fact that we only identified sympto-
matic patients who underwent ultrasonographic exami-
nation. Recent studies which used prospective designs and
screened for venous thrombosis in the absence of clinical
symptoms suggest that catheter-related thrombosis is a
complication that may be more prevalent than clinically
perceived, with incidence rates as high as 64.5% [18,33].
In conclusion we observed a higher incidence of
thrombotic events in hemato-oncology patients with
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higher rate of post-thrombotic complications, notably
infection. Our findings have potential clinical implica-
tions where physicians have to weigh the risk and benefit
of either PICC or CVC for central venous access, as this
can potentially impact the long-term management of pa-
tients with hematological malignancies.
Future randomized controlled trials comparing PICCs
against LTSTCs are required which are adequately po-
wered to detect differences in both short-term and long-
term outcomes (i.e. PE, hospitalization rates and mortality
rates). Further data is also required to address the ongoing
debate on the use of pharmacological thromboprophylaxis
in patients with central venous access, with a particular
focus on those with hematological malignancies.
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